WO2022041803A1 - 一种可视化放射性炭微球及其制备方法和用途 - Google Patents
一种可视化放射性炭微球及其制备方法和用途 Download PDFInfo
- Publication number
- WO2022041803A1 WO2022041803A1 PCT/CN2021/089200 CN2021089200W WO2022041803A1 WO 2022041803 A1 WO2022041803 A1 WO 2022041803A1 CN 2021089200 W CN2021089200 W CN 2021089200W WO 2022041803 A1 WO2022041803 A1 WO 2022041803A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- visualized
- radioactive
- radionuclide
- carbon
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 120
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 90
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 48
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 47
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052726 zirconium Inorganic materials 0.000 claims abstract description 33
- 238000003384 imaging method Methods 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 23
- 239000000243 solution Substances 0.000 claims description 124
- 230000001225 therapeutic effect Effects 0.000 claims description 30
- 150000003384 small molecules Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical group OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 claims description 20
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 229910052765 Lutetium Inorganic materials 0.000 claims description 12
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 12
- 229910052689 Holmium Inorganic materials 0.000 claims description 11
- 229910052772 Samarium Inorganic materials 0.000 claims description 11
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 11
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 11
- 239000001488 sodium phosphate Substances 0.000 claims description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 11
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000012800 visualization Methods 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229940126585 therapeutic drug Drugs 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 4
- XVMIKRZPDSXBTP-UHFFFAOYSA-N 1,3-dibromobutan-2-one Chemical compound CC(Br)C(=O)CBr XVMIKRZPDSXBTP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000003575 carbonaceous material Substances 0.000 claims description 3
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000001179 sorption measurement Methods 0.000 description 17
- 238000002600 positron emission tomography Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- 241000283977 Oryctolagus Species 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 6
- 239000002331 radioactive microsphere Substances 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 210000002767 hepatic artery Anatomy 0.000 description 4
- 201000002313 intestinal cancer Diseases 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 230000005461 Bremsstrahlung Effects 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- the organic small molecule is 5-sulfosalicylic acid, 5-nitrosalicylic acid or a small molecule with similar structure obtained by simple chemical transformation.
- the carbon microspheres after adsorbing the radionuclide for therapy are mixed and reacted with the sodium phosphate solution, and then allowed to stand for 2min-20min, washed and separated into solid-liquid to obtain the first intermediate;
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 一种可视化放射性炭微球混悬液,其特征在于,每1ml该溶液中包含:炭微球10-500mg,治疗用放射性核素活度5-500mCi,显像用放射性核素活度0.1-100mCi,有机小分子0-100mg,第一溶液0.1-1.0ml。
- 如权利要求1所述的混悬液,其特征在于,所述炭微球为通过任意方法所制得的富含微孔和介孔的球形或非球形炭材料,直径为0.05-1000μm,优选20-60μm。
- 如权利要求1所述的混悬液,其特征在于,所述有机小分子为5-磺基水杨酸、5-硝基水杨酸或通过简单化学改造得到的结构相近的小分子。
- 如权利要求1所述的混悬液,其特征在于,所述治疗用放射性核素选自钇[ 90Y]、镥[ 177Lu]、钬[ 166Ho]、钐[ 153Sm]和它们的同位素中任一种,所述显像用放射性核素为锆[ 89Zr]。
- 如权利要求1所述的混悬液,其特征在于,所述第一溶液包括但不限于乙醇溶液、聚乙二醇溶液、甘油溶液;葡糖糖溶液、右旋糖苷溶液、葡聚糖溶液等水溶性糖类溶液;羧甲基纤维素钠溶液、羧乙基纤维素钠溶液、羟丙基纤维素溶液等水溶性纤维素溶液;羟乙基淀粉溶液、羧甲基淀粉钠溶液等水溶性淀粉溶液;以及其它结构相近的水溶性小分子或高分子溶液。
- 一种如权利要求1-5任一项所述可视化放射性炭微球混悬液的制备方法,其特征在于,该方法包含以下步骤:将治疗用放射性核素溶液与具有第一pH值的有机小分子水溶液混合均匀;用炭微球吸附上述混合溶液中的治疗用放射性核素;将吸附治疗用放射性核素后的炭微球与磷酸钠溶液混合反应,清洗并固液分离后得到第一中间体;将第一中间体与具有第一pH值的有机小分子水溶液混合均匀,得到第一中间溶液;向第一中间溶液中加入具有第二pH值的放射性锆[ 89Zr]离子溶液,得到第二中间体;以及向第二中间体加入第一溶液混合均匀并灭菌。
- 一种如权利要求1-5任一项所述可视化放射性炭微球混悬液的制备方法,其特征在于,该方法包含以下步骤:用炭微球吸附具有第一pH值的有机小分子水溶液中的有机小分子;用上述吸附有机小分子后的炭微球吸附放射性锆[ 89Zr],得到第三中间体;用第三中间体吸附治疗用放射性核素离子与有机小分子水溶液混合溶液中的治疗用放射性核素;将吸附治疗用放射性核素后的第三中间体与磷酸钠溶液混合反应,清洗并固液分离后得到第四中间体;以及向第四中间体加入第一溶液混合均匀并灭菌。
- 如权利要求6或7所述的方法,其特征在于,所述第一pH值为1-14,优选3.5-6.5;所述第二pH值为1-14,优选3.5-7.5。
- 一种采用6-8任一所述方法制备得到的可视化放射性炭微球混悬液。
- 一种如权利要求1-5、9任一所述的可视化放射性炭微球混悬液用于制备可视化肿瘤治疗药物中的用途,其中,所述肿瘤包含但不限于肝癌、胰腺癌、肾癌、乳腺癌、甲状腺癌、肠癌实体肿瘤和骨科肿瘤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/916,080 US20230181773A1 (en) | 2020-08-26 | 2021-04-23 | Visualizable radioactive carbon microsphere (cms), preparation method, and use thereof |
EP21859650.0A EP4112085A4 (en) | 2020-08-26 | 2021-04-23 | VISUALIZED RADIOACTIVE CARBON MICRO SPHERE AND PRODUCTION PROCESS AND APPLICATION THEREOF |
AU2021333608A AU2021333608A1 (en) | 2020-08-26 | 2021-04-23 | Visualized radioactive carbon microsphere, and preparation method and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010867997.6 | 2020-08-26 | ||
CN202010867997.6A CN111920968B (zh) | 2020-08-26 | 2020-08-26 | 一种可视化放射性炭微球及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022041803A1 true WO2022041803A1 (zh) | 2022-03-03 |
Family
ID=73304593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/089200 WO2022041803A1 (zh) | 2020-08-26 | 2021-04-23 | 一种可视化放射性炭微球及其制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230181773A1 (zh) |
EP (1) | EP4112085A4 (zh) |
CN (1) | CN111920968B (zh) |
AU (1) | AU2021333608A1 (zh) |
WO (1) | WO2022041803A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111920968B (zh) * | 2020-08-26 | 2023-04-07 | 成都纽瑞特医疗科技股份有限公司 | 一种可视化放射性炭微球及其制备方法和用途 |
CN116603080B (zh) * | 2023-04-04 | 2024-05-28 | 苏州浩微生物医疗科技有限公司 | 一种放射性核素微球及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107303286A (zh) * | 2016-04-14 | 2017-10-31 | 华东理工大学 | 一种明胶杂化复合物及其制备方法和应用 |
CN107715124A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用钇‑90碳微球及其制备方法 |
CN107715122A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用磷酸钇[90y32po4]碳微球及其制备方法 |
CN107715123A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用磷‑32碳微球及其制备方法 |
CN111920968A (zh) * | 2020-08-26 | 2020-11-13 | 成都纽瑞特医疗科技股份有限公司 | 一种可视化放射性炭微球及其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4924604Y1 (zh) * | 1970-09-17 | 1974-07-02 | ||
KR20100135311A (ko) * | 2008-04-24 | 2010-12-24 | 디 오스트레일리언 내셔널 유니버시티 | 거대분자의 방사성 표지화 방법 |
CN101717085B (zh) * | 2009-12-07 | 2012-09-05 | 北京化工大学 | 一种活性碳微球及其制备方法 |
CN102671219B (zh) * | 2011-03-11 | 2013-12-11 | 成都云克药业有限责任公司 | 一种放射性阴离子树脂微球及其制备方法 |
TWI680149B (zh) * | 2018-06-07 | 2019-12-21 | 國立臺北科技大學 | 多孔微球及其製備方法 |
-
2020
- 2020-08-26 CN CN202010867997.6A patent/CN111920968B/zh active Active
-
2021
- 2021-04-23 AU AU2021333608A patent/AU2021333608A1/en active Pending
- 2021-04-23 EP EP21859650.0A patent/EP4112085A4/en active Pending
- 2021-04-23 US US17/916,080 patent/US20230181773A1/en active Pending
- 2021-04-23 WO PCT/CN2021/089200 patent/WO2022041803A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107303286A (zh) * | 2016-04-14 | 2017-10-31 | 华东理工大学 | 一种明胶杂化复合物及其制备方法和应用 |
CN107715124A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用钇‑90碳微球及其制备方法 |
CN107715122A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用磷酸钇[90y32po4]碳微球及其制备方法 |
CN107715123A (zh) * | 2016-08-11 | 2018-02-23 | 李茂良 | 医用磷‑32碳微球及其制备方法 |
CN111920968A (zh) * | 2020-08-26 | 2020-11-13 | 成都纽瑞特医疗科技股份有限公司 | 一种可视化放射性炭微球及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
FISCHER GABRIEL ET AL.: "89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges", MOLECULES, vol. 18, 3 June 2013 (2013-06-03), pages 6469 - 6490, XP055147850, DOI: 10.3390/molecules18066469 * |
See also references of EP4112085A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20230181773A1 (en) | 2023-06-15 |
EP4112085A1 (en) | 2023-01-04 |
AU2021333608A1 (en) | 2022-10-20 |
CN111920968A (zh) | 2020-11-13 |
CN111920968B (zh) | 2023-04-07 |
EP4112085A4 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2574347B1 (en) | Microspheres comprising therapeutic and diagnostic radioactive isotopes | |
Shultz et al. | Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model | |
CA2897362C (en) | Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer | |
Zhao et al. | Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions | |
WO2022041803A1 (zh) | 一种可视化放射性炭微球及其制备方法和用途 | |
CN101801421B (zh) | 含有发射正电子的无机颗粒的组合物及其在医学中尤其是对于诊断过程的应用 | |
WO2022041802A1 (zh) | 一种锆炭微球混悬液及其制备方法和用途 | |
KR20090053783A (ko) | 감마 섬광조영술 평가를 위한 제형의 방사선표지 방법 | |
US9731037B2 (en) | Scanning suspension comprising a particle with a diameter of at least 1 micrometer | |
WO2022134408A1 (zh) | 一种放射性玻璃微球注射剂及制备方法和用途 | |
JP2020504106A (ja) | 標的投与のための放射性標識物質 | |
TW508243B (en) | Novel radiopharmaceutical compositions and matrices and uses thereof | |
CN114504661B (zh) | 一种荷载177Lu的可降解高分子材料微球及其制备方法和应用 | |
Gao et al. | Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy | |
WO2021238529A1 (zh) | 一种锝炭微球注射液及其制备方法和用途 | |
WO2022134409A1 (zh) | 一种放射性树脂微球注射剂及制备方法和用途 | |
TW201615229A (zh) | 製備放射標靶藥物的套件及放射標靶藥物之製造方法 | |
US20100258138A1 (en) | Radiolabeled 1-acetate pet imaging for radiotherapy in head and neck cancer | |
Sinilkin et al. | Experimental Investigation of 99mТс-Nanotech Used for Lymph Nodes Visualization | |
Goldberg et al. | Evaluation of the Potential of Microspherical Systems for Regional Therapy in the Tumor-Bearing Liver and Kidney Using Techniques in Nuclear Medicine | |
WO2022134407A1 (zh) | 一种放射性炭微球注射剂及制备方法和用途 | |
Bakker et al. | Feasibility of unenhanced CT quantification of holmium microspheres for treatment of local tumors | |
CN118141957A (zh) | 一种放射性碘标记的微球及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21859650 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021859650 Country of ref document: EP Effective date: 20220927 |
|
ENP | Entry into the national phase |
Ref document number: 2021333608 Country of ref document: AU Date of ref document: 20210423 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |